Redeye leaves a comment following OncoZenge’s announcement of a SEK2m bridge financing from major shareholder Linc, aimed at supporting the company through the final stage of its European CTA review. While the delayed formal approval extends the regulatory timeline somewhat, we are encouraged to see that OncoZenge has acted swiftly to secure short-term liquidity and maintain full momentum in its preparations for the upcoming pivotal Phase III trial of BupiZenge.
LÄS MER
